Lori A. Leslie, MD, discusses the current treatment options for patients with mantle cell lymphoma.
Lori A. Leslie, MD, lymphoma attending, John Theurer Cancer Center, discusses the current treatment options for patients with mantle cell lymphoma (MCL).
MCL is a very complicated lymphoma, Leslie says. In the upfront setting, physicians should consider factors like age, comorbidities, and what is driving the lymphoma, such as a P53 abnormality. The treatment options in this setting include high-dose chemotherapy and autologous stem cell transplant.
For patients with MCL who are older and less fit, options include bendamustine/rituximab (Rituxan)-like regimens. In a rare subset of patients with MCL, the watch and wait approach could be appropriate, but this is less common in MCL than in other indolent lymphomas.
Overall, Leslie says that she encourages participation in clinical trials for MCL. There are many ongoing studies right now evaluating novel agents, BTK inhibitors, BCL2 inhibitors, combination regimens, and more.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More